{"id":960791,"date":"2026-05-11T09:24:44","date_gmt":"2026-05-11T13:24:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/"},"modified":"2026-05-11T09:24:44","modified_gmt":"2026-05-11T13:24:44","slug":"ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/","title":{"rendered":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101"},"content":{"rendered":"
\n

\n Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape\u00a0<\/em>\n <\/p>\n

\n Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies<\/em>\n <\/p>\n

\n Access the segment <\/em>
\n
\n here<\/em>
\n <\/a>\n <\/p>\n

\n Company to also participate in Virtual Investor Closing Bell event on May 13 featuring Sanjeev Luther and Dr. Robert Pierce<\/em>\n <\/p>\n

\n Register for the Closing Bell event\u202f<\/em>
\n
\n here<\/em>
\n <\/a>
\n \u00a0<\/em>\n <\/p>\n

CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics<\/u><\/a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, Chief Scientific Officer<\/a> of Ernexa.
\u202f\u00a0
As part of the segment, Dr. Pierce provides insight into the complexities of ovarian cancer, one of the most challenging malignancies to treat, and discusses the limitations of current therapeutic approaches. The discussion highlights the patient journey from diagnosis through treatment, emphasizing the persistent unmet need for more effective and durable treatment options.<\/p>\n

Dr. Pierce also outlines the evolving treatment landscape and shares his perspective on how Ernexa is approaching ovarian cancer differently at the biological level. He discusses the Company\u2019s lead product candidate, ERNA-101, and its potential to improve outcomes and enhance the patient experience compared to existing therapies.<\/p>\n

The Virtual Investor KOL Connect segment featuring Ernexa Therapeutics is now available here<\/a>.<\/p>\n

In addition, Ernexa announced that Sanjeev Luther, President & Chief Executive Officer, and Dr. Robert Pierce, Chief Scientific Officer, will participate in a Virtual Investor Closing Bell<\/a> event on Wednesday, May 13, 2026, at 4:00 PM ET.<\/p>\n

As part of the event, Mr. Luther and Dr. Pierce will provide a corporate overview and discuss Ernexa\u2019s recently announced preclinical ovarian cancer data for ERNA-101, which demonstrated complete tumor elimination and 100% survival in ovarian cancer models when combined with PD-1 blockade. The discussion will also cover the potential for ERNA-101 to address immunologically \u201ccold\u201d tumors by reshaping the tumor microenvironment to support stronger immune responses.<\/p>\n

For more information about ERNA-101 and the Company\u2019s development plans, visit www.ernexatx.com<\/a><\/p>\n

\n About Ernexa Therapeutics<\/strong>\n <\/p>\n

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa\u2019s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa\u2019s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.<\/p>\n

ERNA-101 is the company\u2019s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company\u2019s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.<\/p>\n

For more information, visit www.ernexatx.com<\/u><\/a>.<\/p>\n

\n Media Contact<\/strong>
\n
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com<\/u><\/a><\/p>\n

\n Investor Contact<\/strong>
\n
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape\u00a0 Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Access the segment here Company to also participate in Virtual Investor Closing Bell event on May 13 featuring Sanjeev Luther and Dr. Robert Pierce Register for the Closing Bell event\u202f here \u00a0 CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, Chief Scientific Officer of Ernexa.\u202f\u00a0As part of the segment, Dr. … <\/p>\n

Continue reading “Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-960791","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nErnexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape\u00a0 Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Access the segment here Company to also participate in Virtual Investor Closing Bell event on May 13 featuring Sanjeev Luther and Dr. Robert Pierce Register for the Closing Bell event\u202f here \u00a0 CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, Chief Scientific Officer of Ernexa.\u202f\u00a0As part of the segment, Dr. … Continue reading "Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-11T13:24:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101\",\"datePublished\":\"2026-05-11T13:24:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/\"},\"wordCount\":493,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/\",\"name\":\"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA=\",\"datePublished\":\"2026-05-11T13:24:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/","og_locale":"en_US","og_type":"article","og_title":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - Market Newsdesk","og_description":"Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape\u00a0 Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Access the segment here Company to also participate in Virtual Investor Closing Bell event on May 13 featuring Sanjeev Luther and Dr. Robert Pierce Register for the Closing Bell event\u202f here \u00a0 CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, Chief Scientific Officer of Ernexa.\u202f\u00a0As part of the segment, Dr. … Continue reading \"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-11T13:24:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101","datePublished":"2026-05-11T13:24:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/"},"wordCount":493,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/","name":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA=","datePublished":"2026-05-11T13:24:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNjk2NCM3NTkzOTYzIzIyMTAyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/960791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=960791"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/960791\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=960791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=960791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=960791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}